A Thrice-Weekly Ertapenem Regimen Is Practical for Hemodialysis Patients-Reference-Cited by-同舟云学术

A Thrice-Weekly Ertapenem Regimen Is Practical for Hemodialysis Patients

Published:2019-12 Issue:12 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ueng Yune-Fang¹²³⁴,Wang Hong-Jaan⁵,Wu Shiao-Chi⁶,Ng Yee-Yung⁷⁸

Affiliation:

1. Division of Basic Chinese Medicine, National Research Institute of Chinese Medicine, Taipei, Taiwan, Republic of China

2. Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan, Republic of China

3. Institute of Biopharmaceutical Sciences, School of Pharmacy, National Yang-Ming University, Taipei, Taiwan, Republic of China

4. Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China

5. School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China

6. Institute of Health and Welfare Policy, National Yang Ming University, Taipei, Taiwan, Republic of China

7. Division of Nephrology, Taipei Veterans General Hospital, National Yang Ming University, Taipei, Taiwan, Republic of China

8. Department of Medicine, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan, Republic of China

Abstract

A change of ertapenem dosage from 500 mg daily to thrice weekly, after each hemodialysis session, can maintain the plasma concentration above 2 mg/liter and be practical for hemodialysis patients.

Funder

National Science Council

Taipei Veterans General Hospital

National Yang-Ming University

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01427-19

Reference13 articles.

1. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice

2. Pharmacokinetics of Ertapenem in Patients With Varying Degrees of Renal Insufficiency and in Patients on Hemodialysis

3. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis

4. In vitro activity of ertapenem against selected respiratory pathogens

5. In VitroEvaluation of Ertapenem (MK-0826), a Long-Acting Carbapenem, Tested Against Selected Resistant Strains

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of ertapenem dosing in patients with ESBL producing Enterobacterales infections utilizing renal replacement therapies;The International Journal of Artificial Organs;2024-07-30

2. Ertapenem-induced neurotoxicity in an end-stage renal disease patient on intermittent haemodialysis: a case report;BMC Nephrology;2022-11-08

3. Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis;Drugs;2021-02-16

4. Ertapenem Neurotoxicity in Hemodialysis Patients—Safe and Effective Dosing Is Still Needed: A Retrospective Study and Literature Review;Annals of Pharmacotherapy;2020-07-03

5. Evaluation of OPAT in the Age of Antimicrobial Stewardship;Current Treatment Options in Infectious Diseases;2020-04-29